| ¿µ¹® | serum enzyme | ÇÑ±Û | Ç÷ûȿ¼Ò |
|---|---|---|---|
| ¼³¸í | Ç÷û ³»¿¡ Æ÷ÇԵǾî ÀÖ´Â ¿©·¯ °¡Áö È¿¼Ò¸¦ ÀÏÄ´ ¸»ÀÌ´Ù. |
||
| ¿µ¹® | enzyme | ÇÑ±Û | È¿¼Ò |
|---|---|---|---|
| ¼³¸í | »ý¹°Ã¼ ¼¼Æ÷¼Ó¿¡¼ ÇÕ¼ºµÇ°í, ÁÖ·Î ¼¼Æ÷³»¿¡¼ ÁøÇàµÇ´Â ÈÇйÝÀÀÀ» Ã˸ÅÇÏ´Â ´Ü¹éÁú·Î ½ÃÇè°ü³»¿¡¼µµ °°Àº Ã˸ÅÀÛ¿ëÀ» ÇÑ´Ù. ÀÌ È¿¼Ò´Â ÀΰøÀûÀ¸·Î ¸¸µç ¾î¶² Ã˸ÅÁ¦º¸´Ù ±× ƯÀ̼º°ú Ã˸ÅÀÛ¿ëÀÌ Å¹¿ùÇÑ Æ¯º°ÇÑ »ýüºÐÀÚÀÌ´Ù. ½ÅÁø´ë»ç, Áï ¼¼Æ÷³»¿¡¼ ÀϾ´Â ¹°ÁúÀÇ ÈÇÐÀû º¯È¯Àº È¿¼ÒÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ¸Å¿ì ºü¸£°í ¿øÇÒÇÏ°Ô ÀÌ·ç¾îÁø´Ù. À̰ÍÀº È¿¼ÒÀÇ Ã˸ŠȿÀ²ÀÌ ³ôÀº Á¡°ú È¿¼ÒÀÇ ±âÁú ƯÀ̼º ¶§¹®ÀÌ´Ù. È¿¼Ò¹ÝÀÀÀº »ó¿Â, »ó¾Ð, ÃÖÀû pH µî ÀûÀýÇÑ Á¶°Ç ¾Æ·¡¿¡¼ ÁøÇàµÈ´Ù. ¶Ç È¿¼ÒÀÇ ÁÖü°¡ ´Ü¹éÁúÀ̱⠶§¹®¿¡ ´Ü¹éÁúÀ» º¯¼º½ÃŰ´Â ¿, °»ê, °¾ËÄ®¸®, À¯±â¿ë¸Å µî¿¡ ÀÇÇØ ±× ÀÛ¿ëÀ» ÀҴ´Ù. È¿¼Ò´Â »ýü¿¡ ³Î¸® ºÐÆ÷Çϸç, º¹ÀâÇÏ°í ´Ù¾çÇÑ ´ë»ç¹ÝÀÀÀ» Ã˸ÅÇϱ⠶§¹®¿¡ Á¾·ùµµ ¸¹´Ù. ¾Õ¼ ¸»ÇÑ ¹Ù¿Í °°ÀÌ ´ëºÎºÐÀÇ È¿¼Ò´Â ¼¼Æ÷³»¿¡ Á¸ÀçÇÏÁö¸¸, Ç÷¾×°ú ±×¿ÜÀÇ °£Áú¾×¿¡ µé¾î Àֱ⵵ ÇÏ°í ¼ÒÈÈ¿¼Ò·ùó·³ ü¿Ü·Î ºÐºñµÇ´Â °Íµµ ÀÖ´Ù. |
||
| ¿µ¹® | enzyme-linked immunoabsorbent assay | ÇÑ±Û | È¿¼Ò¸é¿ªÃøÁ¤¹ý |
|---|---|---|---|
| ¼³¸í | È¿¼Ò°áÇո鿪ÈíÂøÁ¦ °ËÁ¤¹ýÀ¸·Î ¹ø¿ªµÇ°í ÀÖ´Ù. ÀÌ ¹ýÀº Ç׿ø(¶Ç´Â Ç×ü)¿¡ ¾ËÄ®¸® Æ÷½ºÆÄŸ¾ÆÁ¦ ¶Ç´Â Æä¸£¿Á½Ãµð¾ÆÁ¦ µîÀÇ »ê¼Ò¸¦ °áÇÕ½ÃÄÑ µÎ°í ±× »ê¼ÒȰ¼ºÀ» ÁöÇ¥·Î »ï¾Æ Ç׿øÇ×ü¹ÝÀÀÀÇ Á¤µµ¸¦ ¾È ´ÙÀ½ ¿©±â¿¡¼ Ç׿ø(¶Ç´Â Ç×ü)ÀÇ ¾çÀ» ±¸ÇÏ´Â °ÍÀÌ´Ù. ÀÌ ¹ýÀÇ ÀÌÁ¡À¸·Î¼ °í°¨µµ, Á¶ÀÛÀÇ °£´ÜÇÔ ¹× ¹æ»ç¼±¸é¿ªÃøÁ¤¹ýó·³ ¹æ»ç¼º¹°ÁúÀ» »ç¿ëÇÏÁö ¾Ê¾Æµµ µÈ´Ù´Â Á¡À» µé ¼ö ÀÖ´Ù. È£¸£¸óÀ̳ª ¸é¿ª±Û·ÎºÒ¸°ÀÇ Á¤·®¹ýÀ¸·Î¼ ÀÀ¿ë µÇ°í ÀÖÀ¸¸ç ÃøÁ¤¿ë ŰƮµµ ½ÃÆÇµÇ°í ÀÌÀÖ´Ù. |
||
| EIA | electroimmunoassay; enzyme immunoassay; enzyme-linked immunosorbent assay; equine infectious anemia;... |
|---|---|
| FIA | fistula in ano; fluorescent immunoassay; focal immunoassay; Freund incomplete adjuvant |
| ELIA | enzyme-linked immunoassay |
| EMIT | enzyme multiplied immunoassay technique |
| HEI | Health Effects Institute; high-energy intermediate; homogenous enzyme immunoassay; human embryonic i... |
| EMIT | Enzyme Immunoassay |
|---|---|
| ELISA | Enzyme Linked Immunoassay |
| ELISA | Enzyme immunoassay |
| Emit | Enzyme multiplied immunoassay |
| EIA | Enzyme-linked immunoassay |
| microparticle enzyme immunoassay | A technique in which the solid-phase support consists of very small microparticles in liquid suspension. Specific reagent antibodies are covalently bound to the microparticles. Antigen, if present, is then "sandwiched" between bound antibodies and antigen-specific, enzyme-labelled antibodies. Antigen-antibody complexes are detected and quantitated by analysis of fluorescence from the enzyme-substrate interaction. Acronym: MEIA (05 Mar 2000) |
|---|---|
| enzyme immunoassay | The general term for an expanding technical arsenal of testing which allows a full range of quantitative analyses for both antigen and antibodies. These tests use colour-changed products of enzyme-substrate interaction (or inhibition) to measure the antigen-antibody reaction. Examples of EIA procedures (EMIT, ELISA, MAC, MEIA) follow. Acronym: EIA (05 Mar 2000) |
| enzyme-multiplied immunoassay technique | A type of immunoassay in which the ligand is labelled with an enzyme, and the enzyme-ligand-antibody complex is enzymatically inactive, allowing quantitation of unlabelled ligand. The test uses antibodies that react only with the particular drug for which the sample is being tested. The antibodies attach themselves to the drug if it is present in the sample. It is not designed to measure amounts of the drug present, only to detect its presence or absence. It is used predominantly, but not exclusively, for the detection of drugs of abuse in the urine. See: competitive binding assay, enzyme-linked immunosorbent assay. (05 Mar 2000) |
| RNA, heterogeneous nuclear | Nuclear nonribosomal RNA larger than about 1000 nucleotides, the mass of which is rapidly synthesised and degraded within the cell nucleus. Some heterogeneous nuclear RNA may be a precursor to mRNA. However, the great bulk of total hnrna hybridises with nuclear DNA rather than with mRNA. (12 Dec 1998) |
| heterogeneous | <pathology> Composed of varied cell types. (16 Dec 1997) |
| heterogeneous catalysis | <chemistry> A form of catalysis in which the catalyst is in different physical state than the reactants. (09 Jan 1998) |
| heterogeneous nuclear RNA | An ill-defined form of RNA, of high molecular weight, that never leaves the nucleus and is thought to be the precursor of messenger RNA. (05 Mar 2000) |
| heterogeneous radiation | Radiation consisting of different frequencies, various energies, or a variety of particles. (05 Mar 2000) |
| heterogeneous system | In chemistry, a system that contains various distinct and mechanically separable parts or phases; e.g., a suspension or an emulsion. (05 Mar 2000) |
| solid phase immunoassay | Immunoassay in which the antigen or serum is bound to a solid surface, such as a microplate wall or the sides of a tube, the other reactants being free in solution. (05 Mar 2000) |
| double antibody immunoassay | A method of separating antibody-bound antigen (e.g., insulin) from free antigen by precipitating the former with antibody specific for immunoglobulin. Synonym: double antibody immunoassay, double antibody method. (05 Mar 2000) |
| immunoassay | <investigation> A process that measures and identifies a specific biological substance such as an antigen. (09 Oct 1997) |
| thin-layer immunoassay | A method for detection of antigen-antibody reactions, applicable to detection of either antigen or antibody, based on the fact that either reactant, when added to a polystyrene surface (such as a well in a polystyrene plate) is adsorbed as a thin layer and acts as an immunosorbent capable of binding with the second reactant. (05 Mar 2000) |
| fluorescence immunoassay | <technique> A sensitive technique which uses fluorescein, a fluorescent molecule, to measure the antigen or antibody concentration in a solution. (09 Oct 1997) |
| fluorescence polarisation immunoassay | A technique which takes advantage of the increased polarisation (non-random propagation of emission) of fluorescent light emissions when a fluorescent labelled antigen is bound by reagent antibody. The higher the concentration of unlabelled patient antigen present in the test mixture, the less bound fluorescent antigen is present and, consequently, the lower the polarisation of the fluorescent light emission. Standard calibration yields quantitative results. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|